Throne Biotechnologies (Throne) is a clinical-stage therapeutic company with a disruptive stem cell technology that can fundamentally reverse type 1 diabetes (T1D), alopecia areata (AA) and other autoimmune diseases through immune education of Stem Cell Educator therapy (“Educator Therapy”) at the root causes. Over last 10 years, international multicenter clinical trials in Spain, China, and the United States have strongly demonstrated the clinical safety and efficacy of Stem Cell Educator therapy in more than 200 patients aged from 3 to 70 years old.
Throne received the approvals from the United States Food and Drug Administration (FDA) by using Stem Cell Educator therapy to treat patients with type 1 diabetes and alopecia areata. These clinical trials have been delayed due to the pandemic. Recently, Throne received the License from the New Jersey Department of Health. We are happy to announce that both clinical trials have been started at Throne in collaboration with Fresenius Medical Care, a renowned healthcare company in North America.
For more information about these two clinical trials, please visit clinicaltrials.gov for type 1 diabetes with an identifier No. NCT04011020 and alopecia areata with an Identifier No. NCT04011748.
